Skip to main content

DVAX

Stock

DVAX

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

DVAX Price
Price Chart

Forward-looking statistics

Beta
0.54
Risk
31.07%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees376
Market cap$1.6B

Fundamentals

Enterprise value$820.0M
Revenue$294.6M
Revenue per employee
Profit margin-20.39%
Debt to equity54.64

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.50
Dividend per share
Revenue per share$2.29
Avg trading volume (30 day)$18M
Avg trading volume (10 day)$20M
Put-call ratio

Macro factor sensitivity

Growth-1.1
Credit+5.6
Liquidity+3.2
Inflation-5.9
Commodities+0.6
Interest Rates-0.5

Valuation

Dividend yield0.00%
PEG Ratio28.53
Price to sales4.19
P/E Ratio28.53
Enterprise Value to Revenue2.78
Price to book2.39

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why

Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (May 8, 2025)
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines.

Benzinga (February 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free